Many studies have shown the prognostic significance of glycated hemoglobin (HbA 1c ) for overall coronary artery disease (CAD). But less is known about the role that HbA 1c played in the prognosis of patients diagnosed with ST-segment elevation myocardial infarction (STEMI).
Introduction
Acute coronary syndrome, which mainly consists of ST-segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina, causes a tremendous medical, social and economic burden worldwide [1, 2] . Globally, Acute coronary syndrome in terms of acute myocardial infarction (AMI) accounts for nearly half of the overall mortality related to cardiovascular disease [1] . Identification of high-risk patients, which enables individual management and tailored treatment, is important to improve prognosis [3] .
Among many prognostic factors, acute hyperglycemia (elevation of plasma glucose) after AMI was recognized as a powerful predictor of mortality in patients with and without diabetes mellitus [4] [5] [6] . However, it was proposed that hyperglycemia might be an index of stress-induced catecholamine release [7] . Hence, glucose level in the early phase of AMI would not necessarily reflect the preadmission glycaemic control [8] . On the contrary, glycated hemoglobin (HbA 1c ), a reflection of average blood glucose concentrations over the past 8-12 weeks, is less susceptible to stress during AMI. In this sense, HbA 1c is superior to plasma glucose in evaluating the association between chronic glucose control and clinical outcomes in patients diagnosed with AMI.
Though many studies have shown the prognostic value of HbA 1c for overall coronary artery disease (CAD) [9] , less is known about the role that HbA 1c played in the prognosis of STEMI. Results from previous studies were controversial [3, 8, [10] [11] [12] [13] [14] . Considering the different management and treatment strategies [15] , the effects that high HbA 1c level have on STEMI patients might differ from other types of CAD. Therefore, a meta-analysis was conducted to investigate the associations between admission HbA 1c level and short-and long-term mortality among patients diagnosed with STEMI.
Methods
The current meta-analysis was reported following Preferred reporting items for systematic reviews and metaanalyses checklist (PRISMA) [16] .
Search strategies
Relevant citations were identified by searching several databases up to March 2016, including PubMed, Web of Science, Embase, Chinese national knowledge infrastructure (CNKI), Chinese biological medicine (CBM) and Wanfang databases. We used the following terms ('glycated hemoglobin', 'glycosylated hemoglobin', 'hemoglobin A1c' or 'HbA 1c '), ('ST-segment elevation myocardial infarction', 'ST elevation myocardial infarction' or 'STEMI') and ('mortality', 'death', 'outcome', 'prognosis', 'MACE', 'major adverse cardiovascular events' or 'major adverse cardiac events') as our searching strategies. Searching results were further restricted to English or Chinese-language and human studies. The reference lists of candidate articles were carefully reviewed to identify relevant studies.
Criteria for study inclusion and exclusion
Citations were separately screened by two investigators (GXL and YL) for eligibility. Studies were included if they met the criteria as follows: 1) prospective studies that investigated the association between HbA 1c and the prognosis of STEMI patients; 2) reported rates of shortand long-term mortality after the diagnosis of STEMI; 3) provided sufficient data for the calculation of relative risk (RR) and its corresponding 95% confidence interval (CI). Studies were excluded according to the following criteria: 1) if the study subjects were non-STEMI patients; 2) conference articles were also excluded because they did not contain enough data to qualify for a meta-analysis; 3) when there were multiple publications from the same population, only the publication with the largest sample size was included.
Data extraction
Data were independently extracted by two authors (GXL and XWH) using a purpose-designed form. Any discrepancy would be resolved by discussing with the third author (JL). The following information was collected: first author, year of publication, geographic location, mean age, reperfusion strategy, diabetic status, sample size and cut-off value of HbA 1c , the clinical endpoints in low and high HbA 1c group, respectively.
Since a threshold of 6.5% HbA 1c level was most widely used in numbers of studies and was recommended by the International Expert Committee to diagnose diabetes mellitus in 2009 [17] , a cut-off value of 6.5% was preferred. Alternative cut-off values were those closest to 6.5%. Clinical endpoints were all-cause mortality at different time points (in-hospital, 30-day and long-term). Sevenday mortality was incorporated into in-hospital mortality. In addition, 1-year mortality was treated as long-term endpoints.
Quality assessment
Newcastle-Ottawa Scale [18] , a nine-star system, was applied to perform quality assessment by two researchers, separately. Studies that were awarded with seven or more stars were considered to be of high quality.
Statistical analysis
Summary estimates of the pooled RRs for the associations between HbA 1c level and risk of clinical outcomes among STEMI patients were combined using the inverse variance method. Between-study heterogeneity was checked using Cochran Q and I 2 statistics. It was considered to be statistically significant when the p-value was lower than 0.05 or I 2 was higher than 50% [19] Then a random-effect model was used for the calculation of pooled RR. Otherwise, it was thought to be insignificant and a fixed-effect model was chosen. To explain heterogeneity, subgroup analyses were conducted according to geographic location, reperfusion strategy, diabetic status, sample size (< 500 or ≥ 500) and cut-off value for each outcome, if applicable. To assess the influence of individual studies on the pooled RRs, sensitivity analyses were conducted by sequentially excluding studies one by one. To further explore possible source of heterogeneity, meta-regression analyses were performed. The potential publication bias was examined using the adjusted rank correlation test and the regression asymmetry test, respectively [20, 21] . In case of publication bias, Copas selection model was applied to identify and correct the asymmetry in the funnel plot [22] . The main analyses were performed using Stata 12.0 (Stata Corporation, College Station, TX, USA). Copas selection model was conducted using R software (version 2.11.1). All statistical tests were two-tailed and p < 0.05 was considered statistically significant.
Results

Eligible studies
According to our initial search strategies, there were 312 citations retrieved from the electronic databases ( Figure 1 ). After scanning the titles, abstracts, reading full texts and hand searching the reference lists of candidate articles, we finally got 19 prospective studies including a total of 35,994 STEMI patients to evaluate the associations between HbA 1c level and their in-hospital, 30-day and long-term mortality. Among these studies, there were 13 studies from Asia [3, 8, 10, 12, 13, [23] [24] [25] [26] [27] [28] [29] [30] , 5 from Europe [11, [31] [32] [33] [34] and 1 from North America [35] . Detailed information of the eligible studies was shown in Table 1 .
Pooled analysis
Of the 19 studies in the current meta-analysis, 12 studies reported data on in-hospital mortality in 29,526 STEMI patients. Our results showed no significant association between HbA 1c level (high vs. low) and in-hospital mortality (RR 1.20, 95% CI 0.95-1.53, p = 0.13) (Figure 2A ). Data on 30-day mortality were available in eight studies, with 11,704 STEMI patients involved. Pooled effects showed a 
Subgroup analyses
As depicted in Table 2 , subgroup analyses for in-hospital mortality based on geographic location, reperfusion strategy, diabetic status, sample size and cut-off value were in accordance with that of pooled analysis.
Subgroup analysis by geographic location showed that HbA 1c level was marginally associated with 30-day mortality among European STEMI patients (RR 1.30, 95% CI 0.99-1.73, p = 0.06), but not in Asian STEMI patients (RR 1.25, 95% CI 0.97-1.60, p = 0.08). Subgroup analysis categorized by reperfusion strategy did not show any significant association between HbA 1c and 30-day mortality among studies in which reperfusion strategy was unspecified. Similarly, the significant association could not be replicated among STEMI patients without previously known diabetes or from larger sample size studies. Variation in cut-off value might have substantial influence on the association between HbA 1c level and 30-day mortality (5.8 to 6.3%, RR 1.56, 95% CI 1.05-2.33, p = 0.03; 6.5%, RR 1.15, 95% CI 0.92-1.45, p = 0.22) ( Table 2) .
As for long-term mortality, results from subgroup analyses according to geographic location, reperfusion strategy and cut-off value were consistent with that in the pooled analyses. Nevertheless, our results indicated that the significant association was slightly affected by diabetic status (for diabetic patients, RR 1.46, 95% CI 0.96-2.22, p = 0.07; for non-diabetic patients, RR 1.32, 95% CI 1.10-1.57, p < 0.01; for patients with diabetic status unspecified, RR 1.90, 95% CI 0.95-3.80, p = 0.07). When stratified by sample size, the association between HAb1c level and long-term mortality turn out to be insignificant among studies with sample size larger than 500 (RR 1.21, 95% CI 0.93-1.58, p = 0.15).
Sensitivity analyses and meta-regression analyses
Sensitivity analyses were conducted by deleting studies one by one to assess the robustness of the results. There were no substantial variations in the pooled RRs after the removal of one study each turn, which confirmed that our results were stable and reliable ( Figure 3A-C) .
Meta-regression analyses showed that none of the following covariates (age, sex ratio, geographic location, reperfusion strategy, diabetic status, sample size and cut-off value) were significantly responsible for the between-study heterogeneity in the associations between HAb 1c level and in-hospital, 30-day and long-term mortality rates (Data not shown).
Publication bias
Judging from Begg's correlation tests (in-hospital mortality: p = 0.84; 30-day mortality: p = 0.90; long-term mortality, p = 0.86) and Egger's regression tests (in-hospital mortality: p = 0.47; 30-day mortality: p = 0.91; long-term mortality, p = 0.24), we found no evidence of publication bias (Table 3) .
Discussion
In the current meta-analysis based on 19 observational studies, we evaluated the association between HbA 1c level and the clinical outcomes among 35,994 patients diagnosed with STEMI. Our results indicated that elevated HbA 1c level was a predictor of higher 30-day mortality, long-term mortality rates. Previous studies pointed out that poor glucose control might contribute to the formation of reactive oxygen species, which would result in myocarditis, myocardial necrosis, impaired endothelial function and compromised recovery from myocardial ischemia injury [36, 37] . Evidence indicated that HbA 1c level was positively associated with left ventricular dysfunction and coronary artery severity among STEMI patients [38, 39] . A randomized controlled trial based on 10,251 type 2 diabetes patients even showed that, participants in the intensive therapy group (HbA 1c < 6.0%) were less likely to experience MI than those in the standard therapy group (HbA 1c < 7.0%-7.9%) [40] . However, no statistical association was found between HbA 1c level and incidence of in-hospital mortality. A likely explanation for this discrepancy is that short-term mortality of STEMI patients mainly depends on reperfusion time, infarcted size, and/or other short-term complications, while the damage caused by uncontrolled glucose requires a longer time to manifest [3] . Therefore, HbA 1c was associated with 30-day and longterm mortality rather than in-hospital mortality.
Our subgroup analysis according to geographic location showed some discrepancies for 30-day mortality. The significant prognostic value of HbA 1c was not observed among studies conducted in Asia, with p = 0.08. The value showed that the association between HbA 1c level and 30-day mortality were not significant when the cut-off value was 6.5%. It was noteworthy that all of the five studies [3, 8, 12, 25, 27] in the 6.5% group were conducted in Asia. As mentioned above, HbA 1c might not have significant prognostic value among Asian STEMI patients (Table 2) .
Study limitations
Some limitations of the current study should be noted. Firstly, as a meta-analysis of observational studies, selection bias could not be avoided. Secondly, though fully adjusted effect sizes were preferred during data collection, many studies reported data in terms of sample size and events and merely crude effect sizes were available. Differences in baseline characteristics (such as age, previous history of CAD and treatment details) between patients with and without a high HbA 1c were not adjusted, which was likely to confound our findings. Thirdly, hazard ratios may be more appropriate for the summary of long term outcomes. However, after carefully examining the included studies, most of them do not offer sufficient data for the calculation of hazard ratios (HR) and few studies [33, 34] reported data in forms of hazard ratios. Therefore, we use RR as a substitute for HR in the summary estimate. Perhaps, future studies should report their results in more details and offer hazard ratios as well. Despite the limitations mentioned above, our meta-analysis significantly enhanced the statistical power by pooling substantial data from different studies. Furthermore, the robustness and reliability of our results were further validated by the sensitivity analyses. 
